Pliant Therapeutics, Inc. reported a net loss of $26.3 million for the third quarter of 2025, a significant decrease from the $57.8 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $125.8 million, down from $160.6 million in the prior year. The reduction in losses is attributed to a decrease in research and development expenses, which fell to $17.9 million in Q3 2025 from $47.8 million in Q3 2024, primarily due to the discontinuation of the BEACON-IPF Phase 2b trial and a reduction in workforce that impacted approximately 45% of employees.
Pliant's total operating expenses for the third quarter were $28.3 million, down from $62.0 million in the previous year. The company’s cash and cash equivalents increased to $93.7 million as of September 30, 2025, compared to $71.2 million at the end of 2024. However, short-term investments decreased significantly from $284.5 million to $148.1 million over the same period. The company’s accumulated deficit now stands at $835.8 million, reflecting its ongoing investment in research and development.
In terms of strategic developments, Pliant has focused on advancing its clinical pipeline, particularly with PLN-101095, a dual-selective inhibitor of integrins αvβ8 and αvβ1, which is currently in a Phase 1 trial for solid tumors resistant to immune checkpoint inhibitors. The company has completed enrollment for all five planned dose cohorts in this trial, with interim data showing a 50% objective response rate in one of the cohorts. Additionally, Pliant has announced the discontinuation of the development of bexotegrast for idiopathic pulmonary fibrosis (IPF) due to an unfavorable risk-benefit profile.
Operationally, Pliant has undergone significant restructuring, which included a workforce reduction aimed at preserving cash reserves following the discontinuation of the BEACON-IPF trial. As of November 1, 2025, the company had 61,449,385 shares of common stock outstanding. The company’s management has indicated that it expects to continue incurring significant losses as it advances its product candidates through clinical development and seeks regulatory approvals. Pliant anticipates that its existing capital resources will be sufficient to fund operations for at least the next 12 months, but acknowledges the need for additional capital to support ongoing and future development activities.
About PLIANT THERAPEUTICS, INC.
Pliant Therapeutics is a biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. Its core pipeline includes oral small molecules targeting integrins to treat idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and resistant solid tumors. The company leverages proprietary biology, medicinal chemistry, and biomarker tools to de-risk and accelerate fibrosis drug development for orphan and high unmet need indications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.